Well they were always my #1 choice and if so... I think a bit of luck and Federal Investigations will have something to do with it. Till then... I wonder what Art Levinston thinks of all these researchers...
Edited by Italy Reviewed by Spain
A little reminder: I guess the world is becoming more and more aware of PS Targeting... and yes, it is crucial for homeostasis. The landscapers surrounding Big Pharma are creating change, helped by empowered patients that want to level the landscape in the favor of better medical treatment for all and this will tilt the scales of power and money into some new hands.
Before we revisit this list again, a new book is out, since March 15, 2016 and one I didn't catch... but some familiar names tied to PS Targeting research:
Comprehensively explores the biology and role of MDSCs in cancer Covers therapeutic targeting via the STAT3 pathway, a major regulatory pathway in MDSCs functions as well as in tumour cells Particularly relevant for scientists working in the pharmaceutical industry and in oncology research
The book starts with an introduction to and history of myeloid-derived suppressor cells (MDSCs), followed by a description of their differentiation, their role in the tumour microenvironment and their therapeutic targeting. It closes with an outlook on future developments. In cancer patients, myelopoiesis is perturbed and instead of generating immunogenic myeloid cells (such as dendritic cells, inflammatory macrophages and granulocytes), there is an increase in highly immature MDSCs. These cells are distributed systemically, resulting in general immunosuppression. They also infiltrate tumours, promoting their progression and metastasis by inhibiting the natural anti-tumour immune response. As these cells also interact with classical anti-neoplastic treatments, they have become major therapeutic targets in the pharmaceutical industry and in oncology research.
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death
Abhishek D. Garg,1,* Lorenzo Galluzzi,2,3,4,5,6 Lionel Apetoh,7,8,9 Thais Baert,10,11 Raymond B. Birge,12 José Manuel Bravo-San Pedro,2,3,4,5,6 Karine Breckpot,13 David Brough,14 Ricardo Chaurio,15 Mara Cirone,16 An Coosemans,10,11 Pierre G. Coulie,17 Dirk De Ruysscher,18 Luciana Dini,19 Peter de Witte,20 Aleksandra M. Dudek-Peric,1 Alberto Faggioni,21 Jitka Fucikova,22,23 Udo S. Gaipl,24 Jakub Golab,25 Marie-Lise Gougeon,26 Michael R. Hamblin,27 Akseli Hemminki,28,29,30 Martin Herrmann,15 James W. Hodge,31 Oliver Kepp,2,3,4,5,32 Guido Kroemer,2,3,4,5,32,33,34 Dmitri V. Krysko,35,36 Walter G. Land,37 Frank Madeo,38,39 Angelo A. Manfredi,40 Stephen R. Mattarollo,41 Christian Maueroder,15 Nicolò Merendino,42 Gabriele Multhoff,43 Thomas Pabst,44 Jean-Ehrland Ricci,45 Chiara Riganti,46 Erminia Romano,1 Nicole Rufo,1 Mark J. Smyth,47,48 Jürgen Sonnemann,49 Radek Spisek,22,23 John Stagg,50 Erika Vacchelli,2,3,4,5,6 Peter Vandenabeele,35,36 Lien Vandenberk,51 Benoit J. Van den Eynde,52 Stefaan Van Gool,51 Francesca Velotti,53 Laurence Zitvogel,6,54,55,56 and Patrizia Agostinis1,*
1Cell Death Research and Therapy Laboratory, Department of Cellular Molecular Medicine, KU Leuven?–?University of Leuven, Leuven, Belgium 2Equipe 11 Labellisée Ligue Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France 3U1138, INSERM, Paris, France 4Université Paris Descartes, Sorbonne Paris Cité, Paris, France 5Université Pierre et Marie Curie, Paris, France 6Gustave Roussy Comprehensive Cancer Institute, Villejuif, France 7U866, INSERM, Dijon, France 8Faculté de Médecine, Université de Bourgogne, Dijon, France 9Centre Georges François Leclerc, Dijon, France 10Department of Gynaecology and Obstetrics, UZ Leuven, Leuven, Belgium 11Laboratory of Gynaecologic Oncology, Department of Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium 12Department of Microbiology, Biochemistry, and Molecular Genetics, University Hospital Cancer Center, Rutgers Cancer Institute of New Jersey, New Jersey Medical School, Newark, NJ, USA 13Laboratory of Molecular and Cellular Therapy, Vrije Universiteit Brussel, Jette, Belgium 14Faculty of Life Sciences, University of Manchester, Manchester, UK 15Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nurnberg, Erlangen, Germany 16Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy 17de Duve Institute, Université Catholique de Louvain, Brussels, Belgium 18Department of Radiation Oncology, University Hospitals Leuven, KU Leuven?–?University of Leuven, Leuven, Belgium 19Department of Biological and Environmental Science and Technology, University of Salento, Salento, Italy 20Laboratory for Molecular Biodiscovery, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven?–?University of Leuven, Leuven, Belgium 21Sapienza University of Rome, Rome, Italy 22SOTIO, Prague, Czech Republic 23Department of Immunology, 2nd Faculty of Medicine, University Hospital Motol, Charles University, Prague, Czech Republic 24Department of Radiation Oncology, Universitätsklinikum Erlangen, Erlangen, Germany 25Department of Immunology, Medical University of Warsaw, Warsaw, Poland 26Biotherapy and Vaccine Unit, Institut Pasteur, Paris, France 27Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, USA 28Cancer Gene Therapy Group, Transplantation Laboratory, Haartman Institute, University of Helsinki, Helsinki, Finland 29Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland 30TILT Biotherapeutics Ltd., Helsinki, Finland 31Recombinant Vaccine Group, Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA 32Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France 33Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France 34Department of Women’s and Children’s Health, Karolinska University Hospital, Stockholm, Sweden 35Molecular Signaling and Cell Death Unit, Inflammation Research Center, VIB, Ghent, Belgium 36Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium 37Molecular ImmunoRheumatology, INSERM UMRS1109, Laboratory of Excellence Transplantex, University of Strasbourg, Strasbourg, France 38Institute of Molecular Biosciences, NAWI Graz, University of Graz, Graz, Austria 39BioTechMed Graz, Graz, Austria 40IRRCS Istituto Scientifico San Raffaele, Università Vita-Salute San Raffaele, Milan, Italy 41Translational Research Institute, University of Queensland Diamantina Institute, University of Queensland, Wooloongabba, QLD, Australia 42Laboratory of Cellular and Molecular Nutrition, Department of Ecological and Biological Sciences, Tuscia University, Viterbo, Italy 43Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany 44Department of Medical Oncology, University Hospital, Bern, Switzerland 45INSERM, U1065, Université de Nice-Sophia-Antipolis, Centre Méditerranéen de Médecine Moléculaire (C3M), Équipe “Contrôle Métabolique des Morts Cellulaires”, Nice, France 46Department of Oncology, University of Turin, Turin, Italy 47Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Insitute, Herston, QLD, Australia 48School of Medicine, University of Queensland, Herston, QLD, Australia 49Department of Paediatric Haematology and Oncology, Children’s Clinic, Jena University Hospital, Jena, Germany 50Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Institut du Cancer de Montréal, Faculté de Pharmacie, Université de Montréal, Montreal, QC, Canada 51Laboratory of Pediatric Immunology, Department of Microbiology and Immunology, KU Leuven?–?University of Leuven, Leuven, Belgium 52Ludwig Institute for Cancer Research, de Duve Institute, Université Catholique de Louvain, Brussels, Belgium 53Department of Ecological and Biological Sciences, Tuscia University, Viterbo, Italy 54University of Paris Sud, Le Kremlin-Bicêtre, France 55U1015, INSERM, Villejuif, France 56Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France
Edited by: Fabrizio Mattei, Istituto Superiore di Sanità, Italy Reviewed by: Luis De La Cruz-Merino, Hospital Universitario Virgen Macarena, Spain; Carlos Alfaro, Clínica Universidad de Navarra, Spain
.. .. It is now clear that cancer cells can succumb to some anticancer therapies by undergoing a peculiar form of cell death that is characterized by an increased immunogenic potential, owing to the emission of the so-called “damage-associated molecular patterns” (DAMPs). The emission of DAMPs and other immunostimulatory factors by cells succumbing to immunogenic cell death (ICD) favors the establishment of a productive interface with the immune system. This results in the elicitation of tumor-targeting immune responses associated with the elimination of residual, treatment-resistant cancer cells, as well as with the establishment of immunological memory. .. ..
Several DAMPs exist that are crucial for the maintenance of tissue homeostasis, and the avoidance of auto-immune responses, as they exert immunosuppressive effects, including phosphatidylserine (PS), annexin A1 (ANXA1), death domain 1a (DD1a), B-cell CLL/lymphoma 2 (BCL2) and some extracellular matrix-derived molecules (Table ?(Table1).1). Accordingly, the blockade of these anti-inflammatory DAMPs accentuates the immunogenic potential of dying cells, or renders immunogenic otherwise tolerogenic forms of cell death (28, 29). Moreover, some danger signals are not always involved in the immunogenicity of cell death, but act as “bystanders.” This is the case for heat shock protein 90?kDa alpha (cytosolic), class A member 1 (HSP90AA1, best known as HSP90) exposed on the cell surface after melphalan treatment (30). Last (but not least), several DAMPs may be subjected to post-translational modifications (e.g., oxidation, reduction, citrullination) that may potentially neutralize, increase, or change their immunogenic properties (31, 32)?–?a process that is still incompletely understood. .. .. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4653610/
-----------------
PS Targeting and mapping all the cellular interactions.... would be a very good way to build a foundation and support platform that will, undoubtedly... make the FDA look rather foolish if they did not approve PS Targeting for combinations with all currently approved FDA drugs, "if" some dots are connected...
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!
